+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID07790510

Evaluating HSK42360-Na Tablets Plus Cetuximab With or Without Chemotherapy for BRAF V600-Mutant Metastatic Colorectal Cancer

Led by Haisco Pharmaceutical Group Co., Ltd. · Updated on 2026-08-27

180

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a Phase III clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary effectiveness of HSK42360-Na tablets combined with cetuximab, with or without chemotherapy, in patients with BRAF V600-mutant metastatic colorectal cancer. This trial includes a dose escalation phase to find the best dose and a cohort expansion phase to assess efficacy and safety in different treatment combinations. In Phase I, participants receive escalating doses of HSK42360-Na tablets orally once, twice, or three times daily combined with cetuximab given intravenously every two weeks. After determining the recommended dose, Phase II includes three groups receiving HSK42360-Na with cetuximab alone or combined with either mFOLFOX6 or FOLFIRI chemotherapy regimens. Treatment continues until disease progression, unacceptable side effects, or withdrawal. Participants undergo tumor assessments every 6 weeks initially and every 8 weeks after 18 months, with safety follow-up 30 days after the last dose and survival follow-up every 3 months. Researchers measure dose-limiting toxicities, maximum tolerated dose, pharmacokinetics, response rates, progression-free and overall survival, and duration of response over up to 36 months to understand treatment effects and safety.

CONDITIONS

Brief Title

HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer

Research Team

L

lin shen

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here